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To describe the relationship between level of fatty infiltration in non-alcoholic fatty liver disease (NAFLD) 
and known risk factors in a population with incidentally discovered findings.  
 
Methods 
This was a retrospective cohort study through chart audit of asymptomatic patients attending an executive 
health screen. Pearson correlation coefficients (r) were calculated between degree of fatty liver infiltration 
and known risk factors of fatty liver disease. 
 
Results 
Thirty-six individuals were included. Participants tended to be male (n=27,75.0%) with high BMI (30.59±3.66 
kg/m2). Nearly half of patients (n=15, 41.7%) had a moderate degree of fatty infiltration. The degree of 
infiltration was positively correlated with BMI, total cholesterol, LDL and triglycerides and negatively 
correlated with weekly alcohol consumption and presence of metabolic syndrome. None of these 
relationships were statistically significant. 
 
Discussion 
The current study investigates the relationship between level of fatty liver infiltration and known pathogenic 
risk factors previously described in the literature. No relationship was found between level of fatty liver 
infiltration and metabolic syndrome, BMI, lipid levels, or alcohol consumption in our population of 
asymptomatic individuals. This study further highlights the need to better identification and management 





The histological representation of hepatic steatosis has been known for centuries. Initial descriptions 
were used in the setting of alcoholic liver disease, however in 1980, a non-alcoholic steatosis was 
described.1 This Non-Alcoholic Fatty Liver Disease (NAFLD) was noted in biopsy samples of patients 
without a history of alcohol abuse or a significant history of alcohol intake.1  
Other distinguishing features are the biochemical patterns: NAFLD is described as having alanine 
aminotransferase (ALT) levels exceeding those of aspartate aminotransferase (AST), while alcoholic 
liver injury is characterized by a high AST:ALT ratio.2  
 
NAFLD is currently defined as macrovesicular steatosis in ≥5% hepatocytes, with the absence of 
secondary causes, such as alcohol or drugs.3,4 It refers to a spectrum of disease from non-alcoholic 
fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) to fibrosis and cirrhosis.2–4 The global 
prevalence is estimated to be around 25%, with a rising incidence due to increasing levels of obesity, 
Type 2 Diabetes Mellitus (T2DM) and metabolic syndrome.2,3,5,6 This prevalence may be 
underestimated due to the asymptomatic nature and prolonged period before progression. NAFLD 
may be initially identified due to derangement of liver function tests or evidence of hepatic steatosis 
on abdominal ultrasound, with the gold standard for diagnosis being liver biopsy.2,4,7  
 
The pathogenesis of NAFLD is related to a decrease in insulin sensitivity and hyperinsulinemia.8 This 
insensitivity results in decreased effects of insulin on the metabolism of both lipids and glucose.9 The 
literature indicates that this effect is not only found in patients with abnormal glucose regulation or 
obesity, but is also observed in some individuals with normal weight and normal glucose tolerance.8,9 
Research supports the connection between metabolic syndrome and NAFLD, with some suggesting 
that the two are merely different facets of the same pathophysiologic mechanism.5 Other proposed 
risk factors for the development of NAFLD include diet high in fats and cigarette smoking.10 However, 
there are still gaps in the literature with regards to the lifestyle factors that predispose individuals to 
developing NAFLD, especially in asymptomatic patients.  
 
The objective of the current study is to describe the relationship between level of fatty infiltration in 






This was a retrospective cohort study through chart audit on individuals attending Bon Secours 
Hospital in Limerick, Ireland for Executive Health Screen between 2011-2018. Data were abstracted 
for individuals with incidental findings of fatty liver on abdominal ultrasound.  
 
The following information was collected from patient charts: age, sex, height, weight, blood pressure, 
total cholesterol, HDL, LDL, triglycerides, fasting glucose, ALT, GGT, smoking status, alcohol 
consumption, and extent of fatty liver infiltration.  
Presence of metabolic syndrome was identified by the presence of three or more of the following: 
abdominal obesity (waist circumference >102 cm in men, >88 cm in women), elevated triglycerides 
(>150 mg/dl or on drug treatment for elevated triglycerides), reduced HDL-C level (<40 mg/dl in men, 
<50 mg/ dl in women or on drug treatment for reduced HDL-C ), hypertension (systolic blood pressure 
>130 mmHg or diastolic blood pressure >85 mm Hg or on antihypertensive drug treatment) and 
impaired fasting glucose (100 - 125 mg/dl or on antidiabetic drug treatment).5  
Level of fatty infiltration was graded as mild, moderate or severe. Above information was collected 
as part of the Executive Health Screen. Individuals were asymptomatic at the time of screening.  
 
Pearson correlation coefficients (r) were calculated between degree of fatty liver infiltration and the 
following: BMI, presence of metabolic syndrome, total cholesterol, LDL, triglycerides, alcohol 
consumption per week. No patients in the current study met criteria for alcoholic fatty liver disease. 
We hypothesized that level of fatty liver infiltration would be positively correlated with all above-
mentioned variables.  
 
Variables were calculated as means and SDs or frequencies and percentages as appropriate. 
Significance level was set to p<0.05. Statistical analysis was performed using the IBM SPSS Statistics 





Demographic data are summarized in Table 1. Thirty-six participants were included in the study. 
Participants in the analysis tended to be male (n=27, 75.0%) with BMI in the class I obesity range 
(BMI=30.59±3.66). A number of participants reported having comorbid conditions (n=19, 52.8%). The 
most commonly reported conditions were dyslipidemia (n=6, 16.7%), hypertension (n=6, 16.7%), 
respiratory conditions (n=3, 8.3%) and thyroid conditions (n=3, 8.3%). Just under half of participants 
(n=17, 47.2%) were not taking any medication. Of participants taking medications, four (11.1%) were 
taking lipid lowering medications, four (11.1%) were on antihypertensive medications and two (5.5%) 
were taking both lipid lowering medications and antihypertensives. Nearly half of patients (n=15, 
41.7%) had a moderate degree of fatty liver infiltration based on ultrasound reports.   
 
 
Table 1. Descriptive statistics for n=36 patients included in study. 
 
Characteristic Values 
Age (years) 59.89 ± 10.29 
Sex (n, % males) 27 (75.0%) 
Body Mass Index (kg/m2) 30.59 ± 3.66 
Blood Pressure (mmHg) 135.31 ± 12.13 / 73.17 ± 6.91 
Alcohol Consumption 
(units/week) 
6.77 ± 8.53 
Metabolic Syndrome (n, % yes) 7 (19.4%) 
Number of Medications 1.89 ± 2.63  
Total Cholesterol 5.19 ± 1.19 
HDL 1.26 ± 0.32 
LDL 3.15 ± 1.06 
Triglycerides 1.68 ± 0.83 
Glucose 5.52 ± 0.54 
ALT 40.72 ± 17.45 
GGT 44.72 ± 55.50 
Level of Fatty Infiltration 
Minor 
Minor to moderate 
Moderate 








Note: Values are mean ± SD, n (%), or as otherwise indicated 
 
 
Level of fatty liver infiltration was negatively correlated with weekly alcohol consumption and 
presence of metabolic syndrome, but positively correlated with BMI, total cholesterol, LDL and 
triglycerides. None of these relationships were statistically significant. Unsurprisingly, presence of 
metabolic syndrome was positively correlated with BMI, r(36)=0.432, p=0.015 and total cholesterol 
was correlated with LDL r(36)=0.797, p<0.001. Complete results for the correlation analysis are found 
in Table 2.  
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The current study was a retrospective chart audit of patients with incidental finding of fatty liver 
disease on Executive Health Screen. It demonstrates that level of fatty liver infiltration is not related 
to metabolic syndrome, BMI, lipid levels, or alcohol consumption.   
 
Participants in the current study were demonstrated to have significant levels of fatty liver infiltration 
while being asymptomatic for any liver pathology. This is similar to reports in the literature, where 
hepatic steatosis was detected incidentally during investigation of other complaints.2,3 While in 
NAFLD there are described patterns of liver biochemical tests,2 there is also evidence that many 
patients will have normal liver function tests.3 This has been a limitation with regards to screening 
for NAFLD in the general population.5 Other limitations have include the low accuracy of non-invasive 
tools and inconsistency of self-reported ethanol ingestion histories.2,5,8  
 
Interestingly, level of fatty liver infiltration in the current study was not found to be related to 
metabolic syndrome. However, these results may be limited by the small sample size of the current 
study. Metabolic syndrome refers to a cluster of risk factors that lead to an increased risk for 
atherosclerotic cardiovascular disease, type 2 diabetes mellitus and chronic kidney disease.5,11 The 
etiology of both metabolic syndrome and NAFLD have been linked to insulin resistance and 
compensatory hyperinsulinemia in patients with obesity and normal body weight.5,8,9,11,12  
 
The results from this study demonstrate a relatively healthy overweight population, with many 
reporting one or no comorbidities. The BMI of the participants reported in the current study is similar 
to the average BMI of those presenting for Executive Health Screen at this institution over the study 
period. The high BMI found in study participants is not surprising as the prevalence of obesity has 
been increasing in Ireland over the last two decades.13 The 2017 Healthy Ireland Survey reported that 
39% of Irish adults were overweight and 23% were obese.14 These numbers increase to 44% in the 
overweight category and 32% in the obese category for adults between the ages of 55-64 years, 
which is the age group captured by the current study.14 Therefore, the population captured by the 
current study may be comparable to the larger population, although further research is needed to 
confirm whether the findings of the current study are generalizable. Other considerations when 
interpreting the results from the current study are recall bias and possible under-reporting of alcohol 
consumption.  
 
Although the initial stages NAFLD are asymptomatic, there are several serious complications that 
must be considered. In some patients with NAFLD, isolated steatosis can progress to advanced stages 
with non-alcoholic steatohepatitis (NASH) and fibrosis, increasing the risk of cirrhosis and 
hepatocellular carcinoma,12 although only a minority of patients will develop these complications of 
chronic liver disease.3 The most commonly described complications and cause of death in patients 
with NAFLD is cardiovascular disease.5,9,15 A large cohort trial has demonstrated a higher 5-year 
health care cost in individuals with NAFLD due to the cardiovascular burden in these individuals.16 
 
Management of NAFLD is crucial in order to minimize complications. Current options depend on 
severity of disease but includes lifestyle modifications and pharmacological treatment.  
Drug treatments assessed in NAFLD seem to differ with respect to cardiometabolic and antifibrotic 
efficacy, suggesting the need to better identify and tailor the most appropriate treatment approach, 
or to use a combination of approaches.12 The assessment and management of blood pressure, lipids, 
weight, smoking status and diabetes control are therefore the basis of management in NAFLD, 
especially in the early stages.3,6 Further longitudinal research is required to better characterize the 
risk profile and impact of treatment in individuals with NAFLD.  
 
To conclude, the current study investigates the relationship between level of fatty liver infiltration 
and known pathogenic risk factors previously described in the literature. No relationship was found 
between level of fatty liver infiltration and metabolic syndrome, BMI, lipid levels, or alcohol 
consumption in our population of asymptomatic individuals. This study further highlights the need to 
better identification and management of NAFLD. 
 
 
Declaration of Conflicts of Interest: 




Dr. Mary Ryan 
Consultant Endocrinologist 









1.  Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences 
with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-438. doi:10.1111/j.1572-
0241.2002.07069.x 
2.  Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. Br Med J. 2014;349. 
doi:10.2307/26516755 
3.  Maurice J, Manousou P. Non-alcoholic fatty liver disease. C Gastroenterol. 2018;18:245-250. 
4.  Neuschwander-Tetri B. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic 
Conference. Hepatology. 2003;37(5):1202-1219. doi:10.1053/jhep.2003.50193 
5.  Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 
2009;13(1):9-19. 
6.  Jepsen P, Grønbaek H. Prognosis and staging of non-alcoholic fatty liver disease: Impact of 
staging on mortality is unclear, and liver biopsy remains the definitive method. Br Med J. 
2011;343(7836):1236. 
 
7.  George ES, Roberts SK, Nicoll AJ, et al. Non Alcoholic Fatty Liver Disease Patients Attending 
Two Metropolitan Hospitals in Melbourne, Australia; High Risk Status and Low Prevalence. 
Intern Med J. 2018;48(11):1369-1376. doi:10.1111/imj.13973 
8.  Lee JH, Rhee PL, Lee JK, et al. Role of Hyperinsulinemia and Glucose Intolerance in the 
Pathogenesis of Nonalcoholic Fatty Liver in Patients with Normal Body Weight. Korean J Intern 
Med. 1998;13(1):10-14. doi:10.3904/kjim.1998.13.1.10 
9.  Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic Fatty Liver Disease A Feature of the 
Metabolic Syndrome. Diabetes. 2001;50:1844-1850. 
10.  Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 
2017;9(16):715-732. doi:10.4254/wjh.v9.i16.715 
11.  Defronzo RA, Ferrannini E. Insulin Resistance: A Multifaceted Syndrome Responsible for 
NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease. Vol 
14.; 1991. 
12.  Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, 
cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 
2019;7(4):313-324. doi:10.1016/S2213-8587(18)30154-2 
13.  Irish Heart Foundation and Social Justice Ireland. Reducing Obesity and Future Health Costs. 
Dublin, Ireland; 2015. 
14.  Healthy Ireland. Healthy Ireland Survey: Summary of Findings. Dublin, Ireland; 2017. 
15.  Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and mortality among 
US adults: prospective cohort study. Br Med J. 2011;343(7836):1245. doi:10.1136/bmj.d6891 
16.  Baumeister SE, Völzke H, Marschall P, et al. Impact of Fatty Liver Disease on Health Care 
Utilization and Costs in a General Population: A 5-Year Observation. Gastroenterology. 
2008;134(1):85-94. doi:10.1053/j.gastro.2007.10.024 
 
 
 
 
 
 
 
 
 
